FindTrial
Sign In

Study to check safety and effectiveness of cilnidipine, metoprolol succinate and chlorthalidone in Indian hypertensive patients.

A prospective, observational, Multicenter study to evAluate safety and effIcacy of cilniDipine, mEtoprolol succinate and chlorthalidoNe in high risk hypertensive patients

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2019/01/017089
Enrollment
500
Registered
2019-01-15
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I10- Essential (primary) hypertension

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

Aprica Healthcare Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients willing to provide written informed consent form 2.Male or Female patients aged 18 years and above 3.Essential hypertension which is uncontrolled (defined as systolic BP >= 140 mmHg or diastolic BP >= 90 mmHg ) on dual anti-hypertensive agents 4.Patients treated with cilnidipine, metoprolol succinate and chlorthalidone

Exclusion criteria

Exclusion criteria: 1. Patients receiving any other antihypertensive other than cilnidipine, metoprolol succinate and chlorthalidone

Design outcomes

Primary

MeasureTime frame
1. Reduction in Mean Systolic blood pressure 2. Reduction in Mean Diastolic blood pressure 3. Complications Timepoint: 1, 3 and 6 months—

Secondary

MeasureTime frame
1.Demographic data of study participants 2.Socioeconomic status of patient 3. Comorbid conditions 4.Preferred Dose of cilnidipine, metoprolol succinate and chlorthalidone 5. Dosage frequency 6. Administration time 7. Concomitant medications 8. Adverse events Timepoint: 1, 3 and 6 months—

Countries

India

Contacts

Public ContactDr Amit Gajjar

Aprica Healthcare Pvt Ltd,

dramit@aprican.com7573953504

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026